NCT02773784View on ClinicalTrials.gov

Comparison of CNB and Surgical Specimens for ER, PgR, HER2 Status and Ki67 Index in Invasive Breast Cancer.

CompletedOBSERVATIONAL

Enrollment

314

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

June 30, 2016

Study Completion Date

September 30, 2016

Conditions

Invasive Breast Cancer

Interventions

OTHER

immunohistochemistry and/or FISH

Patients with invasive breast cancer diagnosed by core needle biopsy (CNB) and not to receive neoadjuvant system therapy are eligible for this study. ER, PR, Her-2 and Ki67 are determined by immunohistochemistry (IHC) in CNB and surgical specimen. FISH analysis will be carried out in all HER2 2+ samples.

Trial Locations (1)

100142

Peking University Cancer Hospital, Beijing

All Listed Sponsors

lead

Peking University

OTHER

NCT02773784 - Comparison of CNB and Surgical Specimens for ER, PgR, HER2 Status and Ki67 Index in Invasive Breast Cancer. | Biotech Hunter | Biotech Hunter